FibroBiologics (FBLG) Company Report

FibroBiologics announced that the Canadian Intellectual Property Office has issued Canadian Patent No. 3118732, titled "Treatment of Cachexia Using Fibroblast Cells and Products Thereof".
This patent strengthens FibroBiologics' intellectual property portfolio and covers methods and compositions for treating cachexia or related inflammation through the administration of fibroblasts.
Cachexia is a complex metabolic syndrome, and the cachexia market for cancer is projected to hit $3.2 billion by 2032.
The company's CEO, Pete O'Heeron, stated that this milestone expands global IP protection and brings them closer to delivering transformative therapies.

1 day ago

FibroBiologics Provides 2025 Shareholder Update, Highlights Clinical Progress and Financial Milestones

FBLG

New Projects/Investments

Hiring

FibroBiologics raised $7.2 million through registered direct offerings in November and December 2025 and paid off all outstanding debt. The company also appointed Jason D. Davis as CFO in 2025.
The company received HREC approval in Australia for its Phase 1/2 trial of CYWC628 in diabetic foot ulcers in November 2025, with the trial scheduled to start in Q1 2026 and topline results expected before the end of 2026.
A new Investigational New Drug (IND) application for the CYPS317 psoriasis program was filed on December 30, 2025, and the company is advancing CYMS101 for multiple sclerosis towards an IND submission.
FibroBiologics expanded its intellectual property to over 270 issued and pending patents and opened a new 10,000+ square foot laboratory in Houston in 2025.

Jan 7, 2026, 1:30 PM

FibroBiologics Files IND Application for CYPS317

FBLG

New Projects/Investments

Product Launch

FibroBiologics (FBLG) filed a Phase 1/2 Investigational New Drug (IND) application with the U.S. FDA for CYPS317, an allogeneic fibroblast spheroid-based therapy for moderate to severe psoriasis.
This IND filing represents a major advancement for the company's chronic inflammatory disease pipeline, transitioning from preclinical research to clinical development.
Preclinical results for CYPS317 demonstrated its potential to significantly reduce psoriasis disease severity and relapse.
The company aims to initiate first-in-human clinical trials following FDA review, with a goal to achieve IND clearance for all four of its product candidates in 2026.

Dec 31, 2025, 1:30 PM

FibroBiologics Announces Registered Direct Offering

FBLG

FibroBiologics, Inc. announced a registered direct offering for 5,227,275 shares of its common stock at an offering price of $0.33 per share.
Concurrently, the company will issue unregistered warrants to purchase up to 5,227,275 shares of common stock, with an exercise price of $0.33 per share.
The offering is expected to generate approximately $1.7 million in gross proceeds, with a potential additional $1.7 million if the unregistered warrants are fully exercised for cash.
The closing of the offering is anticipated on or about December 16, 2025, and the net proceeds will be used for working capital and general corporate purposes.

Dec 15, 2025, 10:22 PM

FibroBiologics Announces $1.5 Million Registered Direct Offering

FBLG

FibroBiologics entered into definitive agreements on November 24, 2025, for a registered direct offering and concurrent private placement, with the closing expected on or about November 25, 2025.
The company will issue 4,477,614 shares of common stock and warrants to purchase an equal number of shares, both priced at $0.335 per share.
The offering is expected to generate approximately $1.5 million in gross proceeds, with an additional potential $1.5 million if the warrants are fully exercised for cash.
Net proceeds from the offering are intended for working capital and general corporate purposes.
H.C. Wainwright & Co. is acting as the exclusive placement agent, receiving a 7.0% cash fee and a 1.0% management fee of the aggregate purchase price, along with other fees and warrants to purchase 313,433 shares.

Nov 25, 2025, 1:31 PM

FibroBiologics Closes $4 Million Registered Direct Offering

FBLG

Debt Issuance

Convertible Preferred Issuance

FibroBiologics (FBLG) announced the closing of a registered direct offering, generating approximately $4 million in gross proceeds.
The offering included the issuance of 3,540,000 shares of common stock and 8,570,203 pre-funded warrants at a purchase price of $0.3303 per share or pre-funded warrant.
The purchase price was paid with sovereign-issued .9999 fine gold coins, which the company intends to liquidate into United States dollars.
The net proceeds from the offering are intended for general corporate purposes, including the satisfaction of debt.
A concurrent private placement also issued unregistered warrants to purchase up to 12,110,203 shares, which could provide an additional approximately $4.0 million if fully exercised for cash.

Nov 20, 2025, 12:03 AM

FibroBiologics Announces Registered Direct Offering and Private Placement

FBLG

FibroBiologics, Inc. (FBLG) entered into a definitive purchase agreement for a registered direct offering of 3,540,000 shares of common stock and pre-funded warrants to purchase 8,570,203 shares of common stock at a purchase price of $0.3303 per share or pre-funded warrant.
The offering, priced at-the-market under Nasdaq rules, is expected to generate approximately $4.0 million in gross proceeds for the company.
Payment for the shares and pre-funded warrants will be made with sovereign-issued .9999 fine gold coins, which the company intends to liquidate into United States dollars.
In a concurrent private placement, the company will also issue unregistered warrants to purchase up to 12,110,203 shares of common stock, with an exercise price of $0.3303 per share, which could provide an additional $4.0 million if exercised for cash following stockholder approval.
The net proceeds from the offering are intended for general corporate purposes, including the satisfaction of debt.

Nov 19, 2025, 9:53 PM

Get instant answers from SEC filings, earnings calls & more